Scarica l'app Stockscreener
100.04
2.05%
-2.09
Dopo l'orario di chiusura:
102.02
1.98
+1.98%
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
SYRE|Spyre Therapeutics Inc|Price:99.950|Chg%:-2.180 - TradingKey
Spyre Therapeutics Inc (SYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Spyre Therapeutics Inc (SYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spyre Therapeutics Market Sentiment - Benzinga España
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Inc (SYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ETFs Investing in Spyre Therapeutics, Inc Stocks - TradingView
Spyre Therapeutics, Inc. earns Great Place to Work certification for 2026 - Traders Union
SYRE Stock Draws Analyst Upgrades As Volatility Spikes - StocksToTrade
Why Spyre Therapeutics (SYRE) Stock Is Up Today - Moomoo
Spyre Therapeutics stock hits 52-week high at 102.46 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock hits 52-week high at 102.46 USD - Investing.com
Spyre Therapeutics (SYRE) Slides 4.1% as Biotech Sector Faces HeadwindsIchimoku Cloud - dars.gov.et
Mizuho raises Spyre stock price target to $120 on IBD data - Investing.com UK
Spyre Therapeutics, Inc. participates in key Boston investor event - Traders Union
Mizuho raises Spyre stock price target to $120 on IBD data By Investing.com - Investing.com South Africa
SYRE Maintained by Mizuho -- Price Target Raised to $120 - GuruFocus
Mizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating - marketscreener.com
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $119 - Moomoo
Spyre Therapeutics Insider Sold Shares Worth $1,315,346, According to a Recent SEC Filing - Moomoo
SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
Price to sales forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
Price to book forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding? - simplywall.st
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $119 - Moomoo
Spyre Therapeutics Inc. (SYRE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Spyre Therapeutics (SYRE) Draws Bullish Targets Amid Volatile Trading - StocksToTrade
Spyre falls after $2M insider sale - MSN
Spyre Therapeutics (SYRE) Study result Summary - Quartr
Spyre Therapeutics (SYRE) Leerink Global Healthcare Conference 2026 Summary - Quartr
Spyre Therapeutics stock hits 52-week high at 51.08 USD - Investing.com
Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative - Sahm
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock By Investing.com - Investing.com India
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares By Investing.com - Investing.com India
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock - Investing.com
Spyre Therapeutics (SYRE) CFO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares - Investing.com
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares - Investing.com Nigeria
Form 144 SPYRE THERAPEUTICS INC For: 1 July By Investing.com - Investing.com Canada
Form 144 | Spyre Therapeutics(SYRE.US) Director Proposes to Sell 4 Million in Common Stocks - Moomoo
SYRE (NASDAQ) Form 144: Insider sales and 45,000-share notice - Stock Titan
Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $98 - Moomoo
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data (NASDAQ:SYRE) - Seeking Alpha
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):